Xencor, Inc.
Complement component C5 antibodies
Last updated:
Abstract:
The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
Status:
Grant
Type:
Utility
Filling date:
2 Apr 2018
Issue date:
25 Aug 2020